Novo Nordisk says Wegovy approved in China for liver disease MASH (updated)
10/09/2026 09:08
UPDATE 1-Novo Nordisk says Wegovy approved in China for liver disease MASH Adds comment from paragraph 2
STOCKHOLM, Sept 10 (Reuters) - Denmark's Novo Nordisk NOVOb.CO said on Thursday its blockbuster weight-loss drug Wegovy had been approved in China as the first GLP-1 RA class of drugs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
"The liver health-related benefits evidence extends the established evidence for Wegovy from weight management and cardiovascular health to liver health, further supporting its role in the comprehensive management of obesity and related complications," it said in a statement.
(Reporting by Jacob Gronholt-Pedersen, writing by Anna Ringstrom, editing by Essi Lehto)
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals